Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma

Merck said ​on Wednesday it ‌would buy biotech ​Terns ​Pharma in a ⁠deal ​valued at ​up to $6.7 billion, as the ​drugmaker ​races to bolster ‌its ⁠cancer pipeline ahead of the ​looming ​patent ⁠loss for ​its blockbuster ​therapy ⁠Keytruda.